Mendus Q1 2025: Decent progress - Redeye

Redeye provides its comment on Mendus’ Q1 2025 report. CADENCE recently enrolled its first patient, while Mendus continues to focus on becoming phase III-ready with vididencel in AML in H2 2025e, which we believe will lead to business development opportunities. We update our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1103674/mendus-q1-2025-decent-progress?utm_source=finwire&utm_medium=RSS